AlloVir(ALVR) - 2021 Q1 - Quarterly Report

Product Development - The company has generated five innovative, allogeneic, off-the-shelf VST therapy candidates targeting 12 different devastating viruses, with the most advanced candidate being Viralym-M[114] - The company has treated over 275 allogeneic HSCT patients with its VST therapies, demonstrating a high response rate in immunocompromised patients[115] - The company plans to initiate two additional Phase 3 pivotal trials and one Phase 2 proof-of-concept trial for Viralym-M by the end of 2021[115] - The company is advancing ALVR106, targeting respiratory diseases, and ALVR109, targeting SARS-CoV-2, with ongoing clinical trials[116] Financial Performance - The company incurred a net loss of $30.9 million for the three months ended March 31, 2021, with an accumulated deficit of $156.0 million as of the same date[118] - The net loss for the three months ended March 31, 2021, was $30.9 million, compared to a net loss of $9.3 million for the same period in 2020, an increase of $21.6 million[136] - The total operating expenses for the three months ended March 31, 2021, were $30.9 million, compared to $9.8 million for the same period in 2020, marking a change of $21.0 million[137] - Research and development expenses increased to $20.4 million for the three months ended March 31, 2021, compared to $6.8 million for the same period in 2020, reflecting a rise of $13.6 million[140] - General and administrative expenses rose to $10.5 million for the three months ended March 31, 2021, up from $3.0 million in the same period of 2020, an increase of $7.5 million[141] Cash and Investments - As of March 31, 2021, the company had cash, cash equivalents, and short-term investments of $337.0 million, which it believes will fund operations into 2023[121] - Cash, cash equivalents, and short-term investments totaled $337.0 million as of March 31, 2021, which is expected to fund operations into 2023[144] - Net cash used in operating activities was $18.9 million for the three months ended March 31, 2021, compared to $10.5 million for the same period in 2020, an increase of $8.4 million[151] - Net cash provided by investing activities was $64.8 million for the three months ended March 31, 2021, primarily due to investment maturities of $95.0 million[155] Future Outlook - The company expects to incur significant and increasing expenses and operating losses for the foreseeable future as it continues to develop its product candidates and expand its operations[119] - The company anticipates significant increases in research and development and general and administrative costs as it advances its product candidates and operates as a public company[145] - The company plans to raise substantial additional capital in the future to support ongoing clinical trials and product development[140] Accounting and Compliance - The company prepares its unaudited condensed consolidated financial statements in accordance with U.S. GAAP, requiring estimates and judgments that affect reported amounts of assets and liabilities[158] - The company has elected to take advantage of the extended transition period for complying with new or revised accounting standards as an emerging growth company[159] - The company will remain an emerging growth company until it has total annual gross revenues of at least $1.0 billion or the market value of its common shares held by non-affiliates exceeds $700 million[161] - The company is classified as a "smaller reporting company," with a market value of stock held by non-affiliates less than $700 million and annual revenue below $100 million[162] - Recent accounting pronouncements that may impact the company's financial position and results of operations are disclosed in the Quarterly Report[164] - As a smaller reporting company, the company is not required to disclose quantitative and qualitative disclosures about market risk[165] Operational Challenges - The company has not generated any revenue from product sales and relies on equity financings and other capital sources for funding[117] - The company is assessing the impact of the COVID-19 pandemic on its operations, which has caused delays in clinical trials and may affect future development[121] - The company has no ongoing material financing commitments expected to affect liquidity over the next five years, aside from manufacturing, licensing, and lease obligations[143]